Navigation Links
Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP
Date:6/19/2013

Santa Ana, CA (PRWEB) June 19, 2013

McGuff Pharmaceuticals, Inc. continues to pursue the approval of an Abbreviated New Drug Application (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple dose vial; a generic version of Bristol-Myers Squibb’s drug fomerly known as Delalutin™. We are providing this update in response to varied inquiries regarding the anticipated approval and market introduction dates for McGuff’s Hydroxyprogesterone Caproate Injection, USP drug product.

Regarding the status of our pending ANDA, to date, McGuff has responded to all Food and Drug Administration (FDA) inquiries concerning the ANDA submitted in October 2009. While we are hopeful that a final decision will be made soon, McGuff can not predict when the Agency will make it’s final determination concerning the ANDA approval. We remain committed to bringing Hydroxyprogesterone Caproate Injection, USP to market as quickly as possible.

Our commitment to bring cost effective branded and generic injectable drugs to the U.S. and International markets, for the benefit of patients in need, continues to be one of our driving principles.

If you would like more information about this topic or to schedule an interview with Damon P. Jones, Vice President of McGuff Pharmaceuticals, Inc., please contact Maureen French at 800-603-4795 x301 or email mfrench(at)mcguff(dot)com. You may also visit our website at http://www.mcguffpharmaceuticals.com.

About McGuff Pharmaceuticals, Inc.

McGuff Pharmaceuticals is a Food and Drug Administration (FDA) inspected sterile fill manufacturer that maintains a tradition of quality and core competency in both FDA current Good Manufacturing Practices (cGMP) and International Organization for Standardization’s Quality Management Systems (ISO) 9001:2008, a unique combination for any pharmaceutical manufacturer.

The McGuff family of companies provides commercial pharmaceuticals, compounded drugs, nutritional supplements, medical products and contract services used by leading healthcare organizations and professionals.

The McGuff family of companies includes:

McGuff Company, Inc. – Corporate Headquarters and Medical Products Distribution Center

Subsidiaries:

McGuff Pharmaceuticals, Inc. – Commercial drug manufacturing
McGuff Medical Canada, Inc. – Medical products distribution
McGuff Compounding Pharmacy Services, Inc. – Pharmacy and Compounded drugs

Read the full story at http://www.prweb.com/releases/2013/6/prweb10833717.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PET/MR effective for imaging recurrent prostate cancer
2. ENT and Allergy Associates®, LLP Is Bullish on Wall Street; Practice to Expand/Upgrade Current Clinical Office at 150 Broadway in NYC
3. Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies
4. Poliovirus vaccine trial shows early promise for recurrent glioblastoma
5. Hound.com Finds Jobs in South Atlantic and South West Central Regions Mirroring Current Employment Trends
6. Apple Products are Currently Marked Down at SportsFanPlayground.com
7. Seeking Damages From Bullies: New Website, Bullying Decoded, Reviews Current Legal Cases and Statutes
8. Minimal dose CT superior to chest X-ray for detection of recurrent lung cancer
9. Study reports adenoma detection rates are higher than current guidelines suggest in both men and women
10. Current HPV vaccine may not help some women with immune problems
11. Global burden of dengue is triple current estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Lice Troopers, ... lice cases in families with school-aged children since the holiday season. , “It ... holidays with their families, sharing hugs and taking photos, which is the head-to-head gateway ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: